Testing effectiveness (Phase 2)Study completedNCT01200498What this trial is testingStudy of SB939 in Subjects With MyelofibrosisWho this might be right forMyeloproliferative Disorders M.D. Anderson Cancer Center 23
Testing effectiveness (Phase 2)Study completedNCT01787552What this trial is testingA Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFWho this might be right forPrimary MyelofibrosisThrombocytosisEssential Thrombocythemia+7 more Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Study completedNCT02515630What this trial is testingMomelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Who this might be right forPrimary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV) MyelofibrosisPostessential Thrombocythemia (Post-ET) Myelofibrosis Sierra Oncology LLC - a GSK company 41
Large-scale testing (Phase 3)Active Not RecruitingNCT04717414What this trial is testingAn Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell TransfusionsWho this might be right forMyeloproliferative DisordersMyelofibrosisPrimary Myelofibrosis+2 more Celgene 313
Large-scale testing (Phase 3)Active Not RecruitingNCT04468984What this trial is testingStudy of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisWho this might be right forMyelofibrosis (MF) AbbVie 330
Large-scale testing (Phase 3)Looking for participantsNCT07317700What this trial is testingA Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisWho this might be right forMF Chengdu Zenitar Biomedical Technology Co., Ltd 105
Testing effectiveness (Phase 2)Study completedNCT01340651What this trial is testingStudy of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsWho this might be right forMyelofibrosis Incyte Corporation 41
Testing effectiveness (Phase 2)UnknownNCT04485260What this trial is testingAn Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibWho this might be right forMyelofibrosis Kartos Therapeutics, Inc. 36
Large-scale testing (Phase 3)Active Not RecruitingNCT04603495What this trial is testingPhase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Who this might be right forMyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more Novartis Pharmaceuticals 430
Testing effectiveness (Phase 2)Ended earlyNCT02226172What this trial is testingSingle-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibWho this might be right forPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis Pfizer 21
Testing effectiveness (Phase 2)Temporarily pausedNCT01211691What this trial is testingStudy of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)Who this might be right forMyelodysplastic Syndrome (MDS)Myelofibrosis (MF) Humanigen, Inc. 120
Early research (Phase 1)Looking for participantsNCT04771572What this trial is testingStudy of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.Who this might be right forNon Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more Newave Pharmaceutical Inc 100
Early research (Phase 1)Study completedNCT03895112What this trial is testingMPN-RC 118 AVID200 in MyelofibrosisWho this might be right forPrimary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis+2 more John Mascarenhas 21
Large-scale testing (Phase 3)Study completedNCT02101268What this trial is testingEfficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MFWho this might be right forPrimary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Sierra Oncology LLC - a GSK company 156
Testing effectiveness (Phase 2)Study completedNCT00360035What this trial is testingSafety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid MetaplasiaWho this might be right forMyelofibrosis Gemin X 22
Early research (Phase 1)Ended earlyNCT03373877What this trial is testingEvaluation of Ruxolitinib in Combination With PU-H71 for Treatment of MyelofibrosisWho this might be right forMyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera Myelofibrosis+1 more Samus Therapeutics, Inc. 4
Large-scale testing (Phase 3)Ended earlyNCT04551066What this trial is testingTo Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)Who this might be right forMyelofibrosisPrimary MyelofibrosisPost Essential Thrombocythemia Myelofibrosis+1 more Incyte Corporation 252
Large-scale testing (Phase 3)Active Not RecruitingNCT04576156What this trial is testingA Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentWho this might be right forMyelofibrosis Geron Corporation 327
Testing effectiveness (Phase 2)Study completedNCT01392443What this trial is testingAsian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFWho this might be right forPrimary Myelofibrosis (MF)Post-Polycythemia Vera (PV) MFPost-Essential Thrombocythemia (ET) MF Novartis Pharmaceuticals 120
Early research (Phase 1)WithdrawnNCT04283526What this trial is testingStudy of Select Combinations in Adults With MyelofibrosisWho this might be right forPrimary MyelofibrosisMyelofibrosisPMF+2 more Novartis Pharmaceuticals